Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Cogent Biosciences, Inc. COGT

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$-328.9M
$-266.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2020 · Revenue 7.9 · Net income -74.8
10M20M-30M-60M
2017202020232025
Compound annual growth
−2.0%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2020 · Operating -1044.3% · Net -950.4%
-500%-1000%
201720212025
ROE
FY2025 · ROE -73.7%
-50%
201720212025
Three returns, three denominators.

Each USD of equity lost 74 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -266.0
-100M-200M
201720212025

Total assetsUSD 937.6M
EquityUSD 636.4M
CashUSD 312.0M
Gross debtUSD 222.9M
Net debtUSD -89.1M
Current ratio14.23×

The company holds more cash than debt.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
COGT, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B◌◌◌◌◌0.00.00.00.0
Operating income $B−0.3−0.3−0.2−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.3−0.3−0.2−0.1◌◌◌◌◌
Income tax $B0.0◌◌◌◌◌◌◌◌
Net income $B−0.3−0.3−0.2−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.3−0.2−0.2−0.1−0.1◌−0.0−0.0−0.0
EPS, diluted $−2.16−1.94−1.94−1.73−1.87−16.17−4.18−1.39−2.51
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−73.7−99.5−74.9−59.7−32.2−56.2−69.2——
Shares out B0.160.110.090.070.040.030.030.030.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 4 failures in 36 reconciliationsAUDITED

Reconciled in 5 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency4 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2016

Share this section

Download image